1150102-47-8

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-N1-methylbenzene-1,2-diamine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs. Its unique structure allows for the creation of complex molecules with potential therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Bromo-N1-methylbenzene-1,2-diamine is utilized as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its role in these applications is crucial for enhancing crop protection and improving agricultural yields.
Used in Medicinal Chemistry and Drug Discovery:
6-Bromo-N1-methylbenzene-1,2-diamine is employed as a building block in medicinal chemistry for its potential to form new compounds with therapeutic applications. Its versatility in organic synthesis makes it a valuable tool in drug discovery, where it can be used to create molecules with specific biological activities.
Overall, 6-Bromo-N1-methylbenzene-1,2-diamine is a multifaceted chemical compound with a wide range of applications across different industries, particularly in the development of pharmaceuticals and agrochemicals, as well as in the field of medicinal chemistry and drug discovery.

Upstream product

• 58534-94-4 2-fluoro-3-bromonitrobenzene 
• 1004618-77-2 2-bromo-N-methyl-6-nitro-aniline 

Downstream Products

• 913297-44-6 7-bromo-1-methyl-1,3 -dihydro-2H-benzo[d]imidazol-2-one 

Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF

Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

CRYSTALLINE FORMS OF IRAK DEGRADERS

The present disclosure relates generally to various forms, salts and compositions of compounds useful for the modulation of one or more interleukin-1 receptor-associated kinases ("IRAK") via ubiquitination and/or degradation and uses of the same in the tr

DEUTERATED IRAK DEGRADERS AND USES THEREOF

The present invention provides deuterium-enriched compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.